BMS profits hit by subprime crisis

What's a drugmaker doing, investing in securities at least partly backed by subprime mortgages? Ask Bristol-Myers Squibb, which took a $275 million write-down on so-called "auction rate securities" that had fallen in value to $419 million from $811 million. It also recorded a $142 million loss from a "temporary" plunge in the value of similar securities without subprime backing.

At the time BMS made these investments, the securities had triple-A status with the ratings agencies; they were part of the company's cash-management strategy. Now, says CEO James Cornelius, BMS will trade higher yields for safety, boosting its investment in T-bills.

This footnote to BMS's quarterly results shines a bright light on the subprime monster's many tentacles. Persuaded by the ratings' agencies thumbs-up, lots of savvy investors indulged. How many other seemingly conservative investment portfolios have been touched?

- see the release from BMS
- check out this article in the Financial Times
- read the WSJ Health Blog item

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.